DNA methylation profiling of lung adenocarcinomas and patient-matched non-malignant lung
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA578118 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:DNA copy number profiling of lung adenocarcinomas and patient-matched non-malignant lung
| PRJNA579164 | ENA
Project description:Background: Non-small cell lung cancers (NSCLCs) consist of adenocarcinoma (ADC), squamous cell carcinoma (SCC) and other types. Since most NSCLCs are now diagnosed from small biopsies or cytology materials, classification is not always accurate. This is a problem as many therapy regimens and clinical trials are histology-dependent. Specific Aim: To develop an RNA expression signature as an adjunct test for routine histo-pathological classification of NSCLCs. Methods: A microarray dataset of resected ADC and SCC cases was used as the learning set for an ADC-SCC signature. The Cancer Genome Atlas (TCGA) lung RNAseq dataset was used as a validation set. Another microarray dataset of ADCs and non-malignant lung was used as the learning set for a Tumor-Nonmalignant signature. The classifiers were selected as the most differentially expressed genes and sample classification was determined by a nearest distance approach. Results: We developed a 42-gene expression signature that contained many genes used in immunostains for NSCLC typing. Testing of the TCGA and other public datasets resulted in high accuracies (93-95%). We also observed that most non-malignant lung samples were classified as â??adenocarcinomasâ??, so we added 20 genes to differentiate tumor from non-malignant lung. Together, the 62-gene signature can discriminate ADC, SCC, and non-malignant lung. Additionally, a prediction score was derived that correlated both with histologic grading and survival. Summary and significance: Our histologic classifier provides a non-subjective method to aid in the pathological diagnosis of lung cancer and assist enrollment onto histology-based clinical trials 83 lung adenocarcinomas and 83 matched adjacent non-malignant lung were profiled on Illumina WG6-V3 expression arrays
2016-06-01 | E-GEOD-75037 | biostudies-arrayexpress
Project description:Compare the global methylation profile of 20 malignant pleural mesotheliomas and lung adenocarcinomas. A DNA mixture of two normal mesothelium tissues was used as a reference for the mesotheliomas and a mixture of five normal lung tissues used as the reference for the lung adenocarcinomas
2009-12-01 | E-TABM-813 | biostudies-arrayexpress
Project description:Background: Non-small cell lung cancers (NSCLCs) consist of adenocarcinoma (ADC), squamous cell carcinoma (SCC) and other types. Since most NSCLCs are now diagnosed from small biopsies or cytology materials, classification is not always accurate. This is a problem as many therapy regimens and clinical trials are histology-dependent. Specific Aim: To develop an RNA expression signature as an adjunct test for routine histo-pathological classification of NSCLCs. Methods: A microarray dataset of resected ADC and SCC cases was used as the learning set for an ADC-SCC signature. The Cancer Genome Atlas (TCGA) lung RNAseq dataset was used as a validation set. Another microarray dataset of ADCs and non-malignant lung was used as the learning set for a Tumor-Nonmalignant signature. The classifiers were selected as the most differentially expressed genes and sample classification was determined by a nearest distance approach. Results: We developed a 42-gene expression signature that contained many genes used in immunostains for NSCLC typing. Testing of the TCGA and other public datasets resulted in high accuracies (93-95%). We also observed that most non-malignant lung samples were classified as “adenocarcinomas”, so we added 20 genes to differentiate tumor from non-malignant lung. Together, the 62-gene signature can discriminate ADC, SCC, and non-malignant lung. Additionally, a prediction score was derived that correlated both with histologic grading and survival. Summary and significance: Our histologic classifier provides a non-subjective method to aid in the pathological diagnosis of lung cancer and assist enrollment onto histology-based clinical trials
2016-06-01 | GSE75037 | GEO
Project description:Gene function in cancer is often cell type-specific. The epithelial cell-specific transcription factor ELF3 is a documented tumour suppressor in many epithelial tumours yet displays oncogenic properties in others. Here, we show that ELF3 is an oncogene in the adenocarcinoma subtype of lung cancer (LUAD), providing genetic, functional, and clinical evidence of subtype specificity. We discover a region of focal amplification at chromosome 1q32.1 encompassing the ELF3 locus in LUAD which is absent in the squamous subtype. Gene dosage and promoter hypomethylation affect the locus in up to 80% of LUAD analysed. ELF3 expression was required for tumour growth and a pan-cancer expression network analysis supports its subtype and tissue specificity. We further show that ELF3 displays strong prognostic value in LUAD but not LUSC. We conclude that, contrary to many other tumours of epithelial origin, ELF3 is an oncogene and putative therapeutic target in LUAD.
2019-10-23 | GSE139032 | GEO
Project description:Transcriptomes of lung adenocarcinomas
| PRJNA593979 | ENA
Project description:Transcriptomes of lung adenocarcinomas
| PRJNA638137 | ENA
Project description:Gene function in cancer is often cell type-specific. The epithelial cell-specific transcription factor ELF3 is a documented tumour suppressor in many epithelial tumours yet displays oncogenic properties in others. Here, we show that ELF3 is an oncogene in the adenocarcinoma subtype of lung cancer (LUAD), providing genetic, functional, and clinical evidence of subtype specificity. We discover a region of focal amplification at chromosome 1q32.1 encompassing the ELF3 locus in LUAD which is absent in the squamous subtype. Gene dosage and promoter hypomethylation affect the locus in up to 80% of LUAD analysed. ELF3 expression was required for tumour growth and a pan-cancer expression network analysis supports its subtype and tissue specificity. We further show that ELF3 displays strong prognostic value in LUAD but not LUSC. We conclude that, contrary to many other tumours of epithelial origin, ELF3 is an oncogene and putative therapeutic target in LUAD. A subset of this data has been previously published (https://edrn.jpl.nasa.gov/ecas/data/dataset/urn:edrn:COPY_NUMBER_LEV1) PMID: 22412972
2019-10-23 | GSE139294 | GEO
Project description:We performed RNA-seq using 19 human surgically-resected lung adenocarcinomas to investigate of difference between EGFR-mutated and wild-type lung adenocarcinomas.
2020-02-25 | GSE141569 | GEO
Project description:Five colorectal adenocarcinomas and matched normal colonic tissues were analyzed with Affymetrix HG-U133-Plus-2.0 microarrays. Two labs independently generated microarray data with the same array platform on the same biological samples.
2012-10-03 | GSE41328 | GEO